Molecular Diagnostics Can Help Us Select Optimal Treatment for Men with Metastatic Prostate Cancer.

Androgen receptor positive prostate cancer cells respond much better to abiraterone and enzulatamide.

Zytiga: Testosterone HitAndrogen receptor splice variant-7 (AR-V7) is a truncated form of the androgen receptor that lacks the ligand-binding domain, the target of enzalutamide and abiraterone whose presence can be expected to result in non-responsiveness of patients to these medications.  38% of enzalutamide and 20% of abiraterone treated patients had an AR-V7 variant and had inferior (almost non-existent) response to these medications.

This suggests that we can select patients using molecular targeting and improve the chances that medications would benefit them.

If you have any questions, to schedule a consultation or if you need a second opinion, please contact us or call: 646-663-5515



Leave a Reply